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The crystal structure of the Leishmania major surface proteinase
leishmanolysin (gp63)
Edith Schlagenhauf†, Robert Etges‡ and Peter Metcalf*
Background:  Despite their medical importance, there is little available
structural information for the surface antigens of infectious protozoa. Diseases
caused by the protozoan parasite Leishmania are common in many developing
countries. Human infection occurs during the bite of infected sandflies, when
Leishmania promastigote cells from the insect gut enter the bloodstream.
Promastigotes in the blood parasitize macrophages, often causing serious
disease. Leishmanolysin is the predominant protein surface antigen of
promastigotes, and is assumed to have a key role during infection.
Leishmanolysin is a membrane-bound zinc proteinase, active in situ. Similar
molecules exist in other trypanomastid protozoa.
Results:  Two crystal forms of leishmanolysin were obtained from protein
purified from promastigote membranes. A single lead derivative in both crystal
forms was used to solve the structure. The structure reveals three domains, two
of which have novel folds. The N-terminal domain has a similar structure to the
catalytic modules of zinc proteinases. The structure clearly shows that
leishmanolysin is a member of the metzincin class of zinc proteinases.
Conclusions:  The unexpected metzincin features of the leishmanolysin
structure suggest that the metzincin fold may be more widespread than
indicated by sequence homologies amongst existing metzincin zinc proteinases.
The similarity of the active-site structure to previously well characterized
metzincin class zinc proteinases should aid the development of specific
inhibitors. These inhibitors might be used to determine the function of
leishmanolysin in the insect and during mammalian infection, and may aid the
development of drugs for human leishmaniasis.
Introduction
The kinetoplastid protozoan parasites of the genus Leish-
mania cause diseases for which treatment is difficult and
for which no effective vaccine exists [1,2]. Promastigotes
injected during the feeding of infected sandflies parasitize
macrophages, causing symptoms ranging in severity from
self-healing sores, through severely disfiguring mucosal
lesions (espundia), to a fatal systemic infection involving
spleen and bone marrow (kala azar). Promastigotes of all
Leishmania species express an abundant surface glycopro-
tein, leishmanolysin [3], that is thought to be a ligand
involved in the interaction of the parasite with defensive
systems of the host, including components of the comple-
ment system and the macrophage surface [4–6]. Leish-
manolysin is therefore an attractive vaccine candidate [7].
This glycophosphatidylinositol (GPI)-anchored glycopro-
tein [8], was identified as a neutral metalloproteinase with
activity in a broad pH range extending from around pH 6
to 9 (EC 3.4.24.36; leishmanolysin was previously termed
gp63 or PSP promastigote surface proteinase) [9]. Protein
sequence databases currently contain 13 distinct leish-
manolysin sequences which, with the exception of a short
zinc-binding motif (HEXXH), have no apparent homology
to other proteins. Similar molecules occur in Trypanosoma
brucei [10], the parasite causing African sleeping sickness,
and in the insect parasites without mammalian hosts
(Crithidia and Herpetomonas) [3]. At least 60% of the leish-
manolysin residues are strictly conserved, including the
zinc proteinase motif HEXXH and all 19 cysteine residues.
Leishmanolysin is the major protein component of the pro-
mastigote surface (~5 × 105 molecules/cell), where it is enzy-
matically active against polypeptide substrates [9].
Together with the other major cell surface components, the
lipophosphoglycans (LPGs) and glycoinositolphospholipid
(GIPL) [11], it is likely to have important roles in enabling
the small number (< 1000) of promastigotes injected by the
feeding sandfly [12] to reach and infect sufficient
macrophages to establish an infection. Membrane-bound
leishmanolysin expression by amastigotes (the form of
Leishmania within macrophages) is much reduced, although
a soluble form of leishmanolysin is expressed at lower levels
within the lysosome of the parasite [13,14]. The protein is
synthesized in the endoplasmic reticulum where the signal
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sequence is cleaved post-translationally, N-linked carbohy-
drate is added, and the C-terminal ~25 amino acid residues
are replaced with a GPI membrane anchor structure. Subse-
quent proteolytic processing involves the cleavage of a
propeptide, to produce the mature polypeptide chain. In
the case of Leishmania major the mature protein starts at
residue Val100 [15], has carbohydrate attachment sites at
Asn300, Asn407 and Asn534 and terminates at residue
Asn577, which is covalently bound via ethanolamine to the
carbohydrate part of the GPI anchor.
We present here the crystal structure of leishmanolysin.
This is the first structure of a Leishmania surface molecule
to be reported and may also prove to be the first for a
membrane-bound proteinase. We describe the molecule
and show that the active-site region is similar to that of
previously well characterized metzincin class zinc pro-
teinases for which inhibitors already exist, suggesting
future drug design possibilities.
Results and discussion
Overall structure
Leishmanolysin was purified from membrane preparations
of cultured stationary phase L. major strain LRC-L119 pro-
mastigotes [16]. Treatment with phosphatidylinositol-spe-
cific phospholipase C was used to remove the lipid part of
the GPI anchor, and subsequent purification produced
yields sufficient for crystallization trials [15,17]. Tetragonal
crystals diffracting to 2.5 Å obtained with the precipitant
2-methyl-2,4-pentanediol (MPD) were used for much of
the derivative search. Monoclinic crystals diffracting to at
least 1.8 Å were obtained using macroseeding methods with
similar precipitant conditions. The tetragonal and mono-
clinic crystal forms each contain a single leishmanolysin
molecule in the asymmetric unit. The crystallized molecule
is intact solubilized leishmanolysin, with 478 amino acid
residues and three carbohydrate groups including the ~1100
Dalton GPI anchor. The structure was solved using crystals
of both forms derivatized with trimethyllead acetate. Phases
derived from five lead-atom sites found in the monoclinic
cell were sufficient to determine an approximate molecular
boundary. Electron density within the boundary could be
correlated with electron density derived from the single
lead site found in the tetragonal cell and averaging methods
were used to produce an interpretable map.
Leishmanolysin is a compact molecule containing predom-
inantly β sheet secondary structure. This is in contrast to
the only other protozoan surface antigen structures deter-
mined to date: two Trypanosoma brucei variant surface gly-
coprotein (VSG) ~45 kDa N-terminal fragments that are
dimers with elongated coiled α-helical folds [18,19]. The
overall dimensions of the leishmanolysin molecule are
45 × 50 × 70 Å. The protein consists of three domains: the
N-terminal, central and C-terminal domains (Figure 1).
The N-terminal domain was recognized at an early stage of
the structure determination as having a fold similar to that
of the catalytic modules of zinc proteinases [20]. This
domain contains a catalytic zinc atom and an active-site
helix containing the two histidines of the zinc proteinase
sequence motif HEXXH. There are deep surface indenta-
tions at domain interfaces that join the active-site cleft,
which is located between the N-terminal domain and the
central domain of the molecule (Figure 1). The calculated
surface charge distribution shows a large region of negative
charge surrounding the active-site cleft, but charge distrib-
ution features suggesting the orientation of the molecule
on the promastigote membrane are not evident.
N-terminal domain
Three-dimensional structures of zinc proteinases contain-
ing the HEXXH sequence motif have been grouped into
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Figure 1
Leishmanolysin domain structure and surface
representation. (a) Ribbon representation of
the structure with the N-terminal domain
shown in red, the central domain in green, and
the C-terminal domain in blue. Disulfide bonds
are shown in yellow and the active site zinc
atom is represented as a magenta sphere.
The molecule is viewed looking into the active-
site cleft. (b) Surface representation of the
molecule with regions of negative potential
shown in red and positive regions in blue.
two families: the bacterial thermolysins and the metz-
incins (including serralysins, reprolysins, matrixins and
astacin [21]). Molecules of both classes have a major cat-
alytic domain with a topology consisting of two α helices
(A and B) packed against one side of a five-stranded
twisted β sheet. The HEXXH motif is located on helix B
and the two histidine sidechains are ligands of the active
site zinc atom. The N-terminal domain of leishmanolysin
has these basic features (Figures 2 and 3) and includes 40-
and 35-residue inserted ‘flaps’ which cover the side of the
β sheet opposite from the helices (Figure 4). The 40-
residue flap replaces the second strand of the central sheet
in the conserved topology. There are two disulfide bonds
within this domain, one within the 35-residue ‘flap’ and
the other linking the 40-residue flap to strand S11 of the
central sheet, which borders the active-site cleft.
Central domain
Residues 274–391 of leishmanolysin (Figures 2b and 3b)
fold into a compact domain with antiparallel helices H11
and H12 forming the core of the domain together with the
antiparallel sheet formed by strands S13, S14 and S15.
Residues in the long loop joining H11 and H12 form part
of the active site. Strand S16 forms an antiparallel sheet
with strand S6, and in doing so forms the main connection
between the N-terminal and central domains. A single
disulfide bond connects the C terminus of the domain to
the beginning of the long loop between H11 and H12.
Metzincin class zinc proteinases have an extended zinc
proteinase motif HExxHxxGxxH, where the glycine
residue is part of a tight turn at the end of active-site
helix B, allowing the additional histidine of the motif to
form the third ligand of the active site zinc atom. Metz-
incins share two additional structural features, an unusual
tight 1,4 ‘met-turn’ with a conserved methionine at the
base of  the active site, and a following helix (helix C),
which is roughly parallel to the active-site helix B [21].
The central domain of leishmanolysin contains a correspond-
ing met-turn (Asp342–Ala348) and a helix C (H12), but there
is an unexpected 62-amino acid insertion between the
glycine and third histidine residue (Gly271–His334) of the
metzincin motif that represents half of the central domain
(Figure 4). Leishmanolysin is clearly a metzincin class zinc
proteinase, but does not satisfy the defining sequence motif
HExxHxxGxxH because of the insert between the glycine
(Gly271) and the last histidine (His334).
The active site
The geometry of the leishmanolysin active-site residues
in the immediate vicinity of the catalytic zinc atom is
similar to that of other zinc proteinases. The zinc atom is
coordinated to the ε-nitrogen atoms of His264, His268 and
His334 at distances of 2.18 Å, 2.18 Å and 2.12 Å respec-
tively, similar to values observed in other zinc proteinase
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Figure 2
Leishmanolysin domains and secondary structure. (a) The N-terminal
domain containing the active-site helix H8 with the conserved zinc-
binding motif HEXXH. (b) The central domain. Residues in the loop
preceding H12 contribute to the active site: the zinc-binding ligand
His334 and Met345 are structurally conserved in metzincin family
metalloproteinases. (c) The C-terminal domain. Active-site histidine,
glutamate and methionine residues, and disulfide bonds (in yellow) are
shown in ball-and-stick representation; the zinc atom is shown as a
magenta sphere. The elements of secondary structure are color-coded:
random-coil structure is shown in brown, β sheet in green and α and
310 helices are in light and dark blue, respectively.
structures (2.0–2.2 Å) [20]. The arrangement of the three
zinc ligand histidine sidechains (His264, His268 and
His334) and the underlying met-turn methionine
(Met345) are very similar to those for metzincin class zinc
proteinases, such as astacin [22] and collagenase [23]. The
structures of zinc proteinases determined in the absence
of inhibitors have a fourth zinc ligand — a water molecule
— in addition to the three histidine ligands. This water
molecule is held between the zinc and the oxygens of the
conserved glutamic acid in the zinc proteinase motif
HEXXH. Astacin is unusual in having a fifth zinc ligand
— a tyrosine phenolic oxygen. The water molecule zinc
ligand is thought to have a key role in proteolysis, being
the nucleophile which attacks the substrate peptide bond.
Electron density at the expected position of the catalytic
water molecule zinc ligand is absent in the leishmanolysin
electron-density map and the glutamate sidechain is
twisted away from the usual position it adopts in other
zinc proteinases. The leishmanolysin active-site zinc
appears to be pentacoordinated, with two ligands to a
region of connected density modeled as glycine
(Figure 5a). (The origin of this electron density, modeled
as glycine, is unclear. Similar density is seen in both the
monoclinic and tetragonal maps, and although 100 mM
pH 9.5 ethanolamine-HCl and 100 mM pH 9 glycine-
NaOH buffers were used to produce monoclinic crystals,
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Figure 3
The amino acid sequence and secondary
structure elements of leishmanolysin. The
sequences of the three domains are shown:
(a) the N-terminal domain; (b) the central
domain; and (c) the C-terminal domain. In the
sequence, active-site residues are shown in
red, disulfide bonds are indicated by
connecting thin lines, and carbohydrate
attachment residues are marked by *CHO.
Dotted lines below the sequence show
residues which are disordered in the structure.
The GPI anchor is attached to Asn577.
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Structure
only the ethanolamine buffer was used to prepare tetrago-
nal crystals [17]. Both ethanolamine and glycine can be
modeled into the density with similar N–O zinc coordina-
tion and glycine was chosen as it fits the observed electron
density better.)
In the model, one zinc ligand is the glycine amino nitro-
gen which is near to the position normally occupied by the
catalytic water in zinc proteinase structures (Figures 5b,c).
A glycine carboxyl oxygen forms the fifth zinc ligand and
is located near to the position of the phenolic oxygen of
the tyrosine which forms the fifth zinc ligand in astacin
(Figures 5b,c). Similar N–O zinc coordination has been
observed recently in a complex of the metzincin human
matrix metalloproteinase stromelysin-1 with the protein
inhibitor TIMP-1 (tissue inhibitor of metalloproteinase-1),
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Figure 4
The classification of leishmanolysin as a
metzincin class zinc proteinase and
comparisons with collagenase. (a) The
conserved secondary structure elements of
the metzincin family [21]. Leishmanolysin
lacks strand II of the central β sheet and
includes three insertions (colored circles with
number of inserted residues). (b) Ribbon
diagram showing the part of leishmanolysin
(residues 110–366) with the metzincin
structure (grey) and the three insertions
(colored as in (a)) in the standard zinc
proteinase orientation [21]. The conserved
histidine ligands and the met-turn methionine
sidechains are shown in ball-and-stick
representation; the active site zinc atom is
shown as a magenta sphere. The conserved
metzincin secondary structure elements and
the leishmanolysin equivalents are as follows:
metzincin strand I = leishmanolysin strand S3;
III = S10, IV = S11; V = S12; helix A = H3,
H4; B = H8; and C = H12. (c) The metzincin
and leishmanolysin sequence motifs. The
conserved histidine, glycine and methionine
residues are shown in red (additional residues
in the collagenase met-turn are shown in
green). The spacer between the third histidine
and the methionine residues varies between
7–44 residues depending on the metzincin
member. (d–g) Comparison of leishmanolysin
and the metzincin collagenase. The structures
of leishmanolysin and two similar collagenase
catalytic module–inhibitor complexes (PDB
codes 1jap [23] and 1jao [44]) were
superimposed using the program O [36]. (d)
Overlay of the leishmanolysin (orange) and
collagenase (green) active-site regions. (e)
Ribbon diagram of leishmanolysin with
domains coloured as in Figure 1 showing
metzincin core regions (yellow) where
corresponding collagenase Cα atoms are
within 3.6 Å of aligned leishmanolysin
equivalents. The inhibitors of 1jap and 1jao
indicate the position of the active-site cleft.
The inhibitors on the surface of (f) collagenase
and (g) leishmanolysin. The S1′ hole is
marked with an arrow in each figure.
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Structure
involving the amino nitrogen and carbonyl oxygen of the
first residue of the inhibitor [24].
The similarity of leishmanolysin with metzincin class zinc
proteinases extends beyond the immediate vicinity of the
active site zinc atom. When the metzincin human neu-
trophil collagenase (PDB code 1jap [23]) is aligned to leish-
manolysin, 89 corresponding Cα positions in the active-site
regions of the two molecules match with a root mean square
(rms) difference of 1.8 Å (53 of these residues are located in
the leishmanolysin N-terminal domain and 36 in the central
domain; Figure 4e). Leishmanolysin and collagenase share
residues near the active site in addition to the conserved
metzincin motif residues (Figure 4c). The similarity of
leishmanolysin and collagenase in this region is evident in
the active site surface representation, where both molecules
have large S1′ substrate pockets. Collagenase inhibitors in
the structural alignment fit reasonably well to the leish-
manolysin surface (Figures 4f,g).
C-terminal domain
The elongated C-terminal domain of leishmanolysin
(Figures 2c and 3c) consists of mainly antiparallel β strand and
random coil structure with only minor helical contributions.
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Figure 5
The active site of leishmanolysin and
comparison with the metzincin zinc proteinase
astacin. (a) Stereoview figure illustrating the
electron density attributed to a glycine
molecule adjacent to the leishmanolysin active
site zinc atom (magenta sphere). Zinc ligands
are shown in stick representation. The glycine
shown within the density was omitted from the
model during calculation of the simulated
annealing Fo–Fc omit map, shown contoured
at 3.5σ. (b) Stereoview of the leishmanolysin
active site. The zinc atom (magenta sphere) is
shown with five ligands: εN atoms from
His264, His265 and His334 and the amino
nitrogen and a carboxyl oxygen from the
glycine molecule fitted to the electron density
shown in (a). Water molecules are shown as
light grey spheres; atoms are in standard
colors. (c) Stereoview of the active-site of
astacin. The catalytic water (W) is held in
place by the sidechain of Glu93 (cyan lines).
The corresponding water molecule is absent
in leishmanolysin. The five astacin zinc ligands
include the catalytic water and the phenolic
oxygen of Tyr149, which are in similar
positions to bonds to the glycine molecule in
the leishmanolysin model.
E93
Y149
H264 H264H268 H268
H334 H334
E265 E265
Glycine Glycine
H92 H92
E93
H96 H96
H102 H102
Y149
w w
(a)
(b)
(c)
H264 H264H268 H268
H334 H334
E265 E265
Structure
The domain contains six disulfide bonds. The N-terminal
part of the domain contains three two-stranded antiparallel
sheets (formed from strands S17 and S18; S20 and S21; S19
and S22). These sheets are connected via two short helices
(H16 and H17) to an antiparallel six-stranded β sheet
folded into a sandwich structure (comprising strands
S23–28) and this is in turn attached via two short helices
(H19 and H20) to the GPI anchor. The two C-terminal
residues, the GPI anchor, and three other segments of this
domain (indicated in the sequence underlined with dots;
Figures 2c and 3c) have weak electron density, and are
assumed to be either mobile or disordered in the crystal.
There is no evident similarity with known structures or
with the structure of acetylcholinesterase [25], the only
other known structure of a GPI-anchored protein.
Sequence variability
Amino acid sequences of surface antigens from organisms
that infect mammals often show increased variation,
reflecting changes occurring to overcome developing host
immunity. Well characterized examples of antigenic varia-
tion in human pathogens include the evolution of viral coat
protein sequences associated with influenza epidemics
and the extreme variability of VSG sequences expressed
during T. brucei infection. Although there is no evidence
for similar antigenic variation in Leishmania, leish-
manolysin sequences derived from different species do
differ, and developmental changes in the expression of dif-
ferent genes in Leishmania chagasi has been reported [26].
Leishmanolysin genes occur in multiple copies with
genomic complexity ranging from estimates of six genes
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Figure 6
Tree representation of amino acid sequence
distances of leishmanolysin homologs in the
GenBank database. The diagram includes
leishmanolysin sequences from old world
(red) and new world (blue) Leishmania
species, the insect parasite Crithidia
fasciculata and the African trypanosome
Trypanosoma brucei. Distances were
calculated using sequences corresponding to
mature L. major leishmanolysin (residues
100–577). The key gives the GenBank
sequence identification codes and homology
(% identity) with L. major leishmanolysin.
Sequences sharing the L. major GPI anchor
attachment site, Asn577, are marked (g).
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Structure
with five in a single tandem array in L. major [27] to two or
more tandem arrays containing a total of more than 70
gene copies in Leishmania braziliensis [28]. Although
restriction fragment length polymorphism (RFLP) analysis
of natural isolates indicates extensive polymorphism
[28,29], amino acid sequence variability within the coding
region of the mature protein (residues 100–577 for L.
major) is limited [30–32]. Leishmania sequences are at least
60% identical (Figure 6) and the mature proteins share all
18 cysteines, the active site zinc ligand and methionine-
turn residues with the less conserved leishmanolysin
homologs from Crithidia and T. brucei. The L. major carbo-
hydrate-linked residues (Asn300, Asn407 and Asn534) and
the GPI anchor attachment site at Asn577 are not con-
served in Leishmania species. As expected, surface residues
are less conserved than interior residues, and a surface rep-
resentation of variability suggests sequence variability is
correlated with structural flexibility, as indicated by crys-
tallographic B factors (Figure 7). The C-terminal domain is
the least conserved with the three disordered loops
showing the greatest sequence variation (Figure 7).
Discussion
The discovery of a metzincin fold in leishmanolysin raises
interesting questions about the evolutionary relationships
of zinc proteinases and suggests that this fold may be more
widespread than indicated by the metzincin sequence
motif HExxHxxGxxH alone. The 62-residue segment
seen in leishmanolysin, which replaces the two residues
between the glycine and last histidine of the motif, indi-
cates that significant changes can occur in metzincin pro-
teinases close to the active site that are consistent with
proteolytic activity. Because trypanomastids apparently
predate other species where metzincins are known to
occur [33], leishmanolysin may well have existed before
mammalian metzincins. Despite the apparent evolution-
ary gap, the structural similarity seen in the vicinity of the
active site is still sufficient to suggest that existing collage-
nase inhibitors could be adapted to produce specific
inhibitors for leishmanolysin.
Leishmanolysin is a major component of the promastigote
surface, and is probably involved in host–parasite interac-
tions both in infected insects, and in the early stages of
mammalian infection.  Little is known of the role of leish-
manolysin in insects, but similar proteinases occur in insect
parasites without alternative hosts (Crithidia and Her-
petomonas) or in parasites with very different mammalian
host environments (T. brucei), suggesting a primary role for
the proteinase in the insect stage of the Leishmania life
cycle. Mammalian infection is an obligatory stage of the
Leishmania life cycle, so there is likely to be strong selective
pressure on the surface molecules which first contact the
mammalian immune system in order to maximize infection
probability. Immediately after infection promastigotes fix
and activate complement [14] and leishmanolysin has been
shown to reduce subsequent complement-mediated lysis
[34]. C3-opsonized leishmanolysin has been reported to be
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Figure 7
Structural flexibility and sequence variation.
(a) Surface representation of crystallographic
B factors. Red regions indicate ill-defined
parts of the structure where there is weak
electron density and high B factors; green
areas indicate well-defined regions with low B
factors. (b) Skeleton representation showing
the three domains of leishmanolysin (N-
terminal, red; central, green; and C-terminal,
blue). The three segments with ill-defined
structure in the C-terminal domain are shown
in purple. These segments are those shown
underlined with dots in the sequence
(Figure 3) and with magenta bars below in
part (d) of this figure. (c) Surface
representation of sequence variability.
Regions in red differ most in an alignment of
13 leishmanolysin sequences from different
species (Figure 6; regions in green differ
least). (d) Averaged mainchain B factors for
each residue; magenta bars mark the three ill-
defined regions shown in (b) where B > 50.
(e) Sequence variability. The plot shows the
inverse of the per-residue similarity measure
generated by the UWGCG program
PLOTSIMILARITY [45] from the 13 sequence
leishmanolysin alignment. (f) Bar diagram of
the sequence showing the three domains.
Upper red bars show conserved active-site
residues (Figure 5c) and yellow lines indicate
cysteine residues, which are conserved in
leishmanolysin sequences.
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involved in promastigote–macrophage binding [5]. Leish-
manolysin antigen-specific immune responses to pro-
mastigotes and macrophages carrying amastigotes may be
significant and trials of several leishmanolysin-based vac-
cines have been carried out. Although there is no evidence
for antigenic variation in Leishmania, the polymorphism
seen in leishmanolysin sequences from different strains
does allow invariant surface regions to be identified on the
structure which may prove to be useful for future peptide
vaccine studies.
Treatment for leishmaniasis, although usually effective, is
not easy and improved drugs are clearly needed. Further-
more, parasite resistance to the currently used antimonials
has been reported. Leishmanolysin expression in amastig-
otes is low [13], but if a role for the proteinase in chronic
leishmaniasis is established, leishmanolysin inhibitors may
prove medically useful. We expect that the structure
reported here will initially be used to design specific
inhibitors that could be used to investigate the role of
leishmanolysin in both insect and mammalian hosts.
Biological implications
We report here the structure of the leishmanolysin
membrane-bound proteinase. The structure provides
detailed information about the main protein surface
antigen of the infective insect form of Leishmania, a par-
asitic protozoan which causes widespread disease in
many parts of the world. Leishmanolysin is one of the
best characterized of a number of key surface antigens
from medically important pathogenic protozoa, a class
of molecules for which there is as yet very little struc-
tural information. Although most of the leishmanolysin
structure is novel, the region surrounding the active site
is similar to the active-site region of metzincin class zinc
proteinases. The best characterized examples of these
proteinases are secreted extracellular matrix modifying
enzymes, such as collagenase. To date, all metzincin
proteinase sequences include a sequence motif contain-
ing three active-site histidine residues within a short
stretch of 11 amino acids, HExxHxxGxxH. The leish-
manolysin sequence contains only the first two histidine
residues of the motif, and there was no prior reason to
believe that leishmanolysin was a metzincin. The struc-
ture revealed that the third histidine was present, but
separated in the sequence from the first two histidines
by a 62-residue insert. These results demonstrate that
the current 11-residue metzincin sequence motif can
fail to identify metzincins and that extensive changes
can occur in the immediate proximity of the metzincin
active site, presumably while maintaining the geometry
of the active site and proteolytic activity.
Leishmanolysin molecules on the surface of promastig-
otes probably form a significant part of the interface
between the invading parasite cell and the mammalian
host at the time of infection. Mammalian infection is a
necessary step of the Leishmania life-cycle, and because
comparatively few parasite cells are involved at this criti-
cal stage, there is likely to be strong selective pressure on
leishmanolysin to maximize the probability of infection.
Leishmanolysin might act before infection, ensuring
maximum numbers of parasites are produced and
released from the insect, or just after infection by facilitat-
ing binding and entry into target cells. The existence of a
leishmanolysin homolog in Crithidia fasciculata, an insect
parasite with no mammalian host, suggests a primary role
in the insect. The structure should facilitate the develop-
ment of non-toxic specific inhibitors required for experi-
mental work to determine the function of leishmanolysin.
The medical emphasis of Leishmania research has
meant that work has focused on human reactions to
infection, and on vaccination and drug treatment. Leish-
manolysin antibodies do occur in infected individuals
and trials of vaccines containing leishmanolysin have
been carried out, some with promising results. Reducing
infection by stimulating immune responses to promastig-
otes is complicated by the fact that promastigotes target
macrophages, cells which phagocytose microorganisms
and process antigens in the development of the immune
response. The structure may be used in future to design
peptide vaccines that comprise just the appropriate anti-
genic parts of leishmanolysin, producing a specific pro-
tective response. Although the role of leishmanolysin in
the amastigote macrophage form of Leishmania present
in established infection is unknown, inhibitors may
prove to be medically useful and the structure might be
used together with existing zinc-proteinase inhibitors to
develop therapeutic drugs.
Materials and methods
Crystallization, data collection and processing
Membrane-bound GPI-anchored leishmanolysin, isolated from L. major
strain LRC-L119 stationary phase promastigotes, was solubilized by
phospholipase C cleavage of the lipid part of the GPI anchor and puri-
fied as described [16]. Crystallization trials were carried out with the
mature, glycosylated form of the protein, containing 478 amino acid
residues (Val100–Asn577) and the carbohydrate part of the GPI
anchor. Tetragonal (space group P41212, a = b = 63.6 Å, c = 251.4 Å)
and monoclinic (space group C2, a = 107.2 Å, b = 90.6 Å, c = 70.6 Å,
β = 110.6°) crystals were obtained, grown under very similar crystalliza-
tion conditions [17]. Diffraction data (Table 1) from tetragonal crystals
(native; (CH3)3PbAc 2) were recorded on a Siemens X100 multiwire
area detector, and data from native monoclinic crystals (native 1) on a
MAR Research image plate detector, both mounted on a rotating-
anode X-ray source. Data were processed using XDS. A high-resolu-
tion native monoclinic data set (native 2), collected on the synchrotron
beamline X11 at European Molecular Biology Laboratory–Deutsches
Elektronen Synchrotron (EMBL–DESY), Hamburg, was measured on a
MAR detector and processed using the software packages DENZO
and SCALEPACK.
Phasing
The structure was solved using data from the two crystal forms (Table 2).
Unless otherwise specified, programs used for the structure deter-
mination were from the CCP4 suite [35]) and the software package 
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developed in Uppsala [36]. Soaking experiments with the native crystals
(stabilized in 60% (v/v) 2-methyl-2,4-pentanediol, 100 mM Tris-HCl,
pH 8.0, 10 mM MgCl2) provided a single trimethyllead acetate
(25–30 mM, 3–4 weeks) derivative for both crystals forms. Tetragonal
((CH3)3PbAc 1) and monoclinic ((CH3)3PbAc) derivative data were col-
lected on the synchrotron beamline X31 at EMBL/DESY, Hamburg, at
λ = 0.92 Å to optimize the anomalous scattering signal from lead. Data
were recorded on a MAR detector and processed using MOSFLM and
CCP4 programs. Scaling of heavy-atom derivative data and determina-
tion of heavy-atom positions was carried out using CCP4 programs. The
correct enantiomorph P41(3)212 was assigned using anomalous scatter-
ing data from the trimethyllead acetate derivative and a poor independent
mercury acetate derivative. In C2, the anomalous signal contribution was
too weak to distinguish the hand and the less noisier electron-density
map proved to be correct. Heavy-atom parameters were refined and
SIRAS phases calculated using MLPHARE. Solvent-flattened maps in
the monoclinic and tetragonal cells at 3.0 Å and 3.5 Å, respectively,
showed clear molecular boundaries, but were not interpretable. The rela-
tionship between the maps from each crystal form was determined using
AMORE with a ‘bones atom’ search model made from the 3.0 Å C2 map
using the programs O and MAMA. The initial correlation coefficient for
the electron density within the molecular boundary in the two maps was
0.23. A 30 step iterative averaging procedure (using the program RAVE),
density modification (PRISM [37]), and phase combination (SIGMAA),
was applied using data progressively extending from 3.5 to 2.8 Å resolu-
tion. Maps produced in this way were solvent flattened using DM. The
procedure resulted in an interpretable map where the active-site helix and
the zinc proteinase domain β sheet structure could be recognized.
Refinement
Models consisting at first largely of polyalanine were refined (using X-
PLOR [38]) against the amplitudes and experimental phases of both
the monoclinic and tetragonal data sets and 2Fo–Fc maps from each
were averaged for further rebuilding. Refinement with the high-resolu-
tion synchrotron monoclinic data set to 1.86 Å (native 2) and rebuilding
with density-modified maps (using DM) allowed completion of the
model (Table 3). Waters were added using ARP software. All model
building was performed using the program O. Overall, the structure
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Table 1
Crystallographic data.
Crystal Resolution (Å) Multiplicity Completeness (%) Rmerge (%)*
Tetragonal crystals
Native 2.7 4.7 91.8 8.0
(CH3)3PbAc 1 2.85 4.9 99.2 7.5
(CH3)3PbAc 2 3.8 3.1 77.1 14.9
Monoclinic crystals
Native 1 2.8 4.2 87.6 5.3
Native 2 1.86 5.9 99.5 5.8
(CH3)3PbAc 2.5 4.0 99.0 8.6
*Rmerge = Σhkl Σi | Ihkl,i – < I >hkl | / Σ |< I >hkl| × 100%. (CH3)3PbAc, trimethyllead acetate.
Table 2
Phasing statistics.
Derivative No. of sites Riso* dphas (Å)† RCullis‡ Phasing power§
Tetragonal crystals
(CH3)3PbAc 1 1 18.2 3.5 0.73, 0.74 0.7
1.0(CH3)3PbAc 2 1 20.9 3.8 0.73, 0.67 0.7, 1.3
Monoclinic crystals
(CH3)3PbAc 5 10.9 3.0 0.68, 0.78 0.8, 1.0
*Riso = Σ ||FPH| – |FP|| / Σ |FP| × 100%. †dphas, maximum resolution of
phased reflections. ‡RCullis = Σhkl ||FPH ± FP| – FH(calc)| / Σhkl |FPH – FP|.
§Phasing power = Σhkl |FH| / Σhkl | lack of closure |. The pairs of values
given for RCullis and phasing power are for the centric and acentric
reflections, respectively. For the tetragonal crystals the figure of merit
(FOM) within the resolution range 10–3.5 Å was calculated as 0.51
(for centric reflections) and 0.38 (for acentric reflections); the FOM
values for the monoclinic crystals (resolution range 10–3.0 Å) were
0.56 (centric) and 0.30 (acentric).
Table 3
Refinement statistics.
Resolution (Å) 3.36 2.81 2.51 2.30 2.15 2.04 1.94 1.86 5–1.86
Rmerge (%) 4.5 6.9 8.2 9.5 10.3 12.3 15.3 21.4 5.8
Rwork (%)* 15.4 18.5 20.2 21.0 21.5 22.5 23.7 25.8 19.5
Rfree (%)† 19.1 18.3 20.3 21.8 22.9 23.1 24.6 27.2 21.0
*Rwork, the crystallographic R factor calculated using 90% of all data in the resolution range used in refinement of models. †Rfree, R factor calculated
for a randomly selected 10% of data omitted in the model building and refinement process.
maintains very good stereochemical quality with the deviations from
ideality of geometric parameters lying within the ranges expected for
protein structures at this resolution (Table 4; as determined using
PROCHECK). Three amino acid residues are in disallowed phi/psi
regions in the Ramachandran plot: two (Thr499 and Ile502) belong to
a poorly defined surface loop with high B factors and the third (Ile190),
is part of a classic type I γ turn.
Figures
Skeleton representations were made with RIBBONS [39] or MOLSCRIPT
[40] using secondary structure assignments from PROCHECK. The
surface images were made with GRASP [41]. Figure 6 was prepared
using DRAWTREE [42] from a multiple sequence alignment made using
CLUSTALW [43].
Accession numbers
The coordinates of the leishmanolysin structure and high-resolution
data set native 2 have been submitted to the Brookhaven Protein Data
Bank (accession code 1LML).
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